{"type":"trials","record":{"id":29107,"source_id":"clinicaltrials-gov","external_id":"NCT06099912","title":"Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM","brief_summary":"Frailty is dynamic and confers poor outcomes in elderly patients with newly diagnosed multiple myeloma (NDMM), mainly because of the high prevalence of treatment discontinuation due to intolerability. We designed a multi-center prospective study (DynaFiT) based on our real-life practice to evaluate the feasibility and benefits of a dynamic frailty-tailored therapy in elderly patients with different fitness/frailty statuses. Since Dara-based treatment have recently become the new standard regimens, in this amendment of the study, daratumumab added to VRd is recommended as induction therapy regimen.","overall_status":"Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"FengYan Jin","enrollment":131,"countries":["China"],"start_date":"2021-09-08","completion_date":"2029-09-08","last_update_date":"2026-02-12","source_url":"https://clinicaltrials.gov/study/NCT06099912","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:16:08.862442+00:00","last_seen_at":"2026-09-25T06:10:25.747+00:00","metadata":{"sex":"ALL","acronym":"DynaFiT","age_range":"65 Years","comparator":null,"organization":"The First Hospital of Jilin University","interventions":[],"registry_source":"ClinicalTrials.gov","outcome_measures":["Overall response rate (at least PR) on induction therapy — From the date of inclusion to the end of induction therapy,…","Rate of treatment discontinued(TD) — The time from the date of inclusion to the date of treatment discontinued from any…","Treatment related adverse event(TRAE) — Baseline, end of every induction cycle and maintenance cycle, until disease pro…","Early mortality(EM) — The time from the date of inclusion to the date of death from any cause, up to 24 months.","Progression-free survival(PFS) — The time from the date of inclusion to the date of first documented evidence of diseas…","Overall survival (OS) — The time from the date of inclusion to the date of death from any cause, up to 24 months"],"design_description":null,"source_has_results":false},"controlled_terms":["Multiple Myeloma","Frailty"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: frailty.","quality_checked_at":"2026-09-25T06:10:37.875473+00:00","duplicate_cluster_key":"id:nct06099912","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-09-08 to 2029-09-08","comparator":null,"confidence":"structured-source","population":"ALL · 65 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:10:25.801Z","intervention":[],"participants":131,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Overall response rate (at least PR) on induction therapy — From the date of inclusion to the end of induction therapy,…","Rate of treatment discontinued(TD) — The time from the date of inclusion to the date of treatment discontinued from any…","Treatment related adverse event(TRAE) — Baseline, end of every induction cycle and maintenance cycle, until disease pro…","Early mortality(EM) — The time from the date of inclusion to the date of death from any cause, up to 24 months.","Progression-free survival(PFS) — The time from the date of inclusion to the date of first documented evidence of diseas…","Overall survival (OS) — The time from the date of inclusion to the date of death from any cause, up to 24 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"frailty","is_published":true,"match_reasons":["Title contains controlled term: frailty.","Abstract contains controlled term: frailty.","Source terminology contains: frailty.","Title supplies longevity context: frailty, frail.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Frailty","slug":"frailty"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/29107","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}